To investigate whether DF2755A treatment could prevent the onset and development of CYP-induced peripheral neuropathy, DF2755A was administered as preventive chronic treatment 12 h before the first CYP administration (20 mg kg−1) and then twice daily (7 mg kg−1) for 7 days during IC development. Here, PPIG is linked to peripheral neuropathy.